A number of firms have modified their ratings and price targets on shares of Aimmune Therapeutics (NASDAQ: AIMT) recently:

  • 3/6/2018 – Aimmune Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $72.00 price target on the stock.
  • 3/5/2018 – Aimmune Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $64.00 price target on the stock.
  • 3/5/2018 – Aimmune Therapeutics was given a new $47.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 3/5/2018 – Aimmune Therapeutics had its price target raised by analysts at Roth Capital from $75.00 to $80.00. They now have a “buy” rating on the stock.
  • 3/2/2018 – Aimmune Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/27/2018 – Aimmune Therapeutics had its price target raised by analysts at Royal Bank of Canada to $62.00. They now have an “outperform” rating on the stock.
  • 2/27/2018 – Aimmune Therapeutics was given a new $62.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 2/27/2018 – Aimmune Therapeutics was given a new $45.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 2/23/2018 – Aimmune Therapeutics had its “buy” rating reaffirmed by analysts at Wedbush.
  • 2/22/2018 – Aimmune Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 2/20/2018 – Aimmune Therapeutics was given a new $30.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 2/20/2018 – Aimmune Therapeutics was given a new $45.00 price target on by analysts at Credit Suisse Group AG. They now have a “buy” rating on the stock.
  • 2/20/2018 – Aimmune Therapeutics had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They wrote, “Quick thoughts on today’s market reaction. Absent hearing pointed criticism of the PALISADE data, the market’s reaction befuddles us somewhat. We suppose AIMT owners could be taking profits, the stock is +50% since October 20, 2017, as compared with +1% for the NBI. Would-be investors might be disinclined to buy the stock on release of positive top-line results that were anticipated (in one fashion of another) and might desire a view of additional data. We are mindful, too, that the commercial launch of the product is likely 15-18 months hence.””
  • 2/12/2018 – Aimmune Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush.
  • 2/8/2018 – Aimmune Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 2/7/2018 – Aimmune Therapeutics is now covered by analysts at Royal Bank of Canada. They set an “outperform” rating and a $55.00 price target on the stock.
  • 1/31/2018 – Aimmune Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “
  • 1/31/2018 – Aimmune Therapeutics had its price target raised by analysts at Roth Capital from $60.00 to $75.00. They now have a “buy” rating on the stock.
  • 1/30/2018 – Aimmune Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Aimmune Therapeutics Inc (AIMT) opened at $30.11 on Friday. Aimmune Therapeutics Inc has a 1 year low of $15.97 and a 1 year high of $42.00. The stock has a market capitalization of $1,779.78, a PE ratio of -11.54 and a beta of -0.49.

In other Aimmune Therapeutics news, Director Kathryn E. Falberg bought 30,000 shares of Aimmune Therapeutics stock in a transaction that occurred on Monday, February 26th. The shares were bought at an average cost of $32.00 per share, with a total value of $960,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Douglas T. Sheehy sold 1,875 shares of the company’s stock in a transaction dated Tuesday, December 26th. The shares were sold at an average price of $39.44, for a total value of $73,950.00. Following the transaction, the insider now directly owns 1,875 shares in the company, valued at $73,950. The disclosure for this sale can be found here. Over the last ninety days, insiders have purchased 58,093 shares of company stock worth $1,858,976 and have sold 133,968 shares worth $5,073,180. Corporate insiders own 17.59% of the company’s stock.

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.